# EDGAR Filing Document

**Accession Number:** 0001657312
**File Stem:** 0001104659-25-100312
**Filing Date:** 2025-10
**Character Count:** 2914
**Document Hash:** 00a4e90f9db6ccb405df91c4f408e1aa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-100312.hdr.sgml**: 20251017

**ACCESSION NUMBER**: 0001104659-25-100312

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251017

**DATE AS OF CHANGE**: 20251017

**EFFECTIVENESS DATE**: 20251017

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verona Pharma plc
- **CENTRAL INDEX KEY:** 0001657312
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38067
- **FILM NUMBER:** 251399349

**BUSINESS ADDRESS:**
- **STREET 1:** 3 MORE LONDON RIVERSIDE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SE1 2RE
- **BUSINESS PHONE:** 011-44-0-2032834200

**MAIL ADDRESS:**
- **STREET 1:** 3 MORE LONDON RIVERSIDE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SE1 2RE

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER<br> SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION<br> OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE<br> SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number <u>001-38067</u>

---

| |
|:---|
| **Verona Pharma plc** |
| &nbsp;&nbsp;(Exact name of registrant as specified in its charter) |
| **3 More London Riverside**<br> **London SE1 2RE**<br> **United Kingdom**<br> **+44 203 283 4200** |
| &nbsp;&nbsp;(Address, including zip code, and telephone number, including area code, of registrant's <br> principal executive offices) |
| &nbsp;&nbsp;**Ordinary Shares, nominal value £0.05 per share<br> American Depositary Shares, each representing eight ordinary shares** |
| &nbsp;&nbsp;(Title of each class of securities covered by this Form) |
| &nbsp;&nbsp;(Titles of all other classes of securities for which a duty to file reports under section 13(a) or <br> 15(d) remains) |

---

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to<br> terminate or suspend the duty to file reports:<br>

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | x |
| Rule 12g-4(a)(2) | ◻ |
| Rule 12h-3(b)(1)(i) | ⌧ |
| Rule 12h-3(b)(1)(ii) | ◻ |
| Rule 15d-6 | ◻ |
| Rule 15d-22(b) | ◻ |

---

Approximate number of holders of record as of the certification or notice date <u>One (1)</u>

Pursuant to the requirements of the Securities Exchange Act of 1934 Verona Pharma plc has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

**VERONA PHARMA PLC**

---

| | | | |
|:---|:---|:---|:---|
| Date: | October 17, 2025 | By: | /s/ Benjamin Lucas |
|  |  |  | Name: Benjamin Lucas<br> Title: Principal Executive Officer and Director |

---